Drugs / betamethasone dipropionate
betamethasone dipropionate
also known as
diprospan · betamethasone · DFD-01 · Diprosone · BDP · BD spray 0.05% · Betamethasone diproprionate (0.5% ointment USP generic) · Betamethasone-17,21-dipropionate · +11 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed psoriasis 2 milestones | |||||
| Filed | Japan (PMDA) | Dovobet | psoriasis | 2017-06-22 | “LEO Pharma K.K. has filed an application for the manufacturing and marketing approval of this product for psoriasis vulgaris in Japan.” kyowakirin.com ↗ |
| Filed | US (FDA) | — | psoriasis | 2011-02-22 | “today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment” perrigo.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (2) | US (FDA) | DIPROLENE AF | — | 2001-10-03 – 2006-08-28 | fda.gov ↗ |
| Label expansion | US (FDA) | DIPROSONE | — | 1982-07-21 | fda.gov ↗ |
| Approved | US (FDA) | DIPROSONE | — | 1975-01-29 | fda.gov ↗ |
Trials 60
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03898583 | Apr → Oct 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03892564 | Feb → Mar 2019 | phototoxic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03899064 | Feb → Apr 2019 | photoallergic dermatitis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03476746 | Mar → Jul 2018 | — | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03442244 | Jan → Feb 2018 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02355639 | Jan → Apr 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01946386 | Sep → Oct 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01837576 | Apr → Jun 2013 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01466478 | Nov → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05220293 | Feb 2022 → Dec 2023 | chronic rhinosinusitis | Oticara Australia PTY LTD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01768013 | Jul → Oct 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 214 trials · 1 met primary | ||||||
| Phase 2 | NCT05882903 | Aug 2023 → Jun 2025 overdue | chronic rhinosinusitis | Oticara Australia PTY LTD | Recruiting | No outcome recorded |
| Phase 2 | NCT04580537 | Oct 2020 → Jun 2021 | psoriasis | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03819218 | Dec 2018 → Dec 2020 | psoriasis | MC2 Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03462927 | Feb → Aug 2018 | psoriasis | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03026478 | May 2016 → Mar 2018 | lichen planus, oral | Garlapati Komali | Unknown | No outcome recorded |
| Phase 2 | NCT02070965 | Jan → Oct 2014 | psoriasis | Primus Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01229098 | Oct 2010 → Sep 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01120223 | May 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01083758 | Apr 2010 → Aug 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00817219 | Jul 2009 → Dec 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00875277 | Apr → May 2009 | psoriasis | LEO Pharma | Completed | Met primary |
| Phase 2 | NCT00910676 | Oct 2007 → Mar 2009 | colorectal cancer, non-small cell lung carcinoma | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 2 | NCT00820950 | May 2007 → Jan 2009 | psoriasis | Incyte Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00263718 | Dec 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 314 trials · 4 met primary · 2 missed | ||||||
| Phase 3 | NCT02582177 | Jun 2019 → Jan 2020 | tinea infection | Ache Laboratorios Farmaceuticos S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03802344 | Dec 2018 → Oct 2019 | psoriasis | MC2 Therapeutics | Completed | Met primary |
| Phase 3 | NCT03731091 | Oct 2018 → Mar 2020 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02668692 | Feb → Jun 2016 | psoriasis | LEO Pharma | Completed | Missed primary |
| Phase 3 | NCT02527421 | Aug 2015 → Mar 2019 | psoriasis | Primus Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02132936 | Jun 2014 → Feb 2015 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01947491 | Nov 2013 → Jan 2015 | psoriasis | Primus Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01866163 | Jun → Oct 2013 | psoriasis | LEO Pharma | Completed | Met primary |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | Missed primary |
| Phase 3 | NCT00279162 | Dec 2005 → Jul 2007 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00243464 | Sep 2005 → May 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216879 | Feb 2005 → Jul 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00216840 | Dec 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | Met primary |
| Phase 3 | NCT00216827 | Nov 2004 → Sep 2005 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT04227288 | Nov 2021 → Oct 2023 | psoriasis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT05175001 | May 2021 → Jun 2022 | chronic pain syndrome | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| Phase 4 | NCT04555707 | Jun 2020 → Jun 2021 | psoriasis | Derm Research, PLLC | Unknown | No outcome recorded |
| Phase 4 | NCT04372277 | Apr 2020 → Mar 2021 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT04073069 | Sep 2019 → Aug 2020 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04114097 | Aug 2019 → Mar 2021 | atopic eczema | Jacob Thyssen | Completed | No outcome recorded |
| Phase 4 | NCT03827876 | Jan → Sep 2019 overdue | psoriasis | Psoriasis Treatment Center of Central New Jersey | Recruiting | No outcome recorded |
| Phase 4 | NCT03506477 | May 2018 → Sep 2019 | psoriasis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT03848871 | Dec 2017 → Nov 2018 | psoriasis | Derm Research, PLLC | Completed | No outcome recorded |
| Phase 4 | NCT03080545 | May → Oct 2017 | psoriasis | Psoriasis Treatment Center of Central New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT02749799 | Feb → Jul 2016 | psoriasis | Primus Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02004574 | Oct 2013 → Jun 2014 | psoriasis | Jooheung Lee | Completed | No outcome recorded |
| Phase 4 | NCT01761019 | Jan 2013 → Sep 2014 | psoriasis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00248456 | Oct 2005 → Feb 2006 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT07626463 | May 2026 → May 2027 expected | acute cholecystitis | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07337772 | Feb 2026 → Nov 2028 expected | adrenal cortex disorder, osteoarthritis, knee | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| — | NCT06344403 | Jun 2025 → Oct 2026 expected | herpes zoster | Beijing Tiantan Hospital | Active not recruiting | No outcome recorded |
| — | NCT06785350 | Jan → Sep 2025 overdue | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06321354 | Jul → Nov 2024 | — | Beijing Tiantan Hospital | Completed | No outcome recorded |
| — | NCT05926895 | Jun 2023 → Aug 2024 | shoulder impingement syndrome | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT05303766 | Apr 2022 → Mar 2023 | osteoarthritis, knee | Assiut University | Unknown | No outcome recorded |
| Comparator or background therapy39 trials | ||||||
| Phase 1 | NCT03758365 Comparator | Nov 2018 | vascular disorder | MC2 Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03880357 Comparator | Oct 2018 → Mar 2019 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02376049 Comparator | Feb → Jul 2015 | atopic eczema | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03399526 Comparator | Feb → May 2013 | psoriasis | Bayer | Completed | No outcome recorded |
| Phase 1/2 | NCT07256834 Comparator | Nov → Dec 2025 overdue | — | Jinnah Postgraduate Medical Centre | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06332612 Comparator | Aug → Dec 2024 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 2 | NCT03279796 Comparator | Oct 2018 → Dec 2019 | epicondylitis, rotator cuff syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT02518048 Comparator | Aug 2015 → Jan 2016 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02416258 Comparator | Apr → Jun 2015 | connective tissue disorder | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01347255 Comparator | May → Jun 2011 | psoriasis | LEO Pharma | Completed | Met primary |
| Phase 2 | NCT02920658 Comparator | Dec 2010 → Nov 2013 | aphthous stomatitis, lichen planus, oral | Ivan Alajbeg | Completed | Missed primary |
| Phase 2/3 | NCT05981118 Comparator | Jul 2024 → Jul 2026 overdue | — | Wake Forest University Health Sciences | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT04071106 Comparator | Sep → Dec 2019 | psoriasis | Zagazig University | Unknown | No outcome recorded |
| Phase 3 | NCT05983445 Comparator | Jan 2023 → Apr 2024 | gout | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT03806790 Comparator | Jan → Jun 2019 | psoriasis | LEO Pharma | Completed | Missed primary |
| Phase 3 | NCT04000932 Comparator | Jul 2018 → Dec 2019 | carpal tunnel syndrome | Baskent University | Unknown | No outcome recorded |
| Phase 3 | NCT03331523 Comparator | Oct 2017 → Oct 2018 | psoriasis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02899962 Comparator | Feb 2017 → Jun 2019 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01422434 Comparator | Jul 2011 → Apr 2012 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01188928 Comparator | Sep 2010 → Mar 2011 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT07635043 Comparator | Aug → Oct 2026 expected | psoriasis | Pakistan Institute of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07242846 Comparator | Oct → Nov 2025 | osteoarthritis, knee | Nigde Omer Halisdemir University | Completed | No outcome recorded |
| Phase 4 | NCT05475808 Comparator | Aug 2022 → Jul 2023 overdue | carpal tunnel syndrome | Abant Izzet Baysal University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05260125 Comparator | Mar 2022 → Mar 2025 overdue | hemiplegia, stroke disorder | Abant Izzet Baysal University | Recruiting | No outcome recorded |
| Phase 4 | NCT04207931 Comparator | Apr 2018 → Nov 2026 expected | central centrifugal cicatricial alopecia | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT03368274 Background | Sep 2017 → Jun 2018 | immunoglobulin G4-related sclerosing disease | Wen Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT02858713 Background | Jan → Apr 2017 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02833545 Comparator | Sep 2016 → May 2018 | osteoarthritis, knee | Rabin Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03196817 Comparator | Aug 2016 → May 2017 | carpal tunnel syndrome | Hospital Alvorada | Unknown | No outcome recorded |
| Phase 4 | NCT01707043 Comparator | Oct 2012 → Sep 2013 | psoriasis | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT00437255 Comparator | Aug 2006 → Jun 2007 | psoriasis | Galderma R&D | Completed | No outcome recorded |
| — | NCT07626489 Comparator | May 2026 → May 2027 expected | — | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT07002892 Comparator | Jan 2025 → Jan 2026 overdue | carpal tunnel syndrome | Yunus Burak Bayır | Recruiting | No outcome recorded |
| — | NCT06599086 Comparator | Sep 2024 → Sep 2025 overdue | carpal tunnel syndrome | Yunus Burak Bayır | Recruiting | No outcome recorded |
| — | NCT06011083 Comparator | Aug 2022 → Feb 2023 | psoriasis | Assiut University | Completed | No outcome recorded |
| — | NCT05556122 Background | Jul → Dec 2022 | peripheral nerve lesion | Affiliated Hospital of Nantong University | Unknown | No outcome recorded |
| — | NCT04444726 Background | Jan 2019 → Nov 2020 | atopic eczema | Cairo University | Completed | No outcome recorded |
| — | NCT03525522 Comparator | Jan 2016 → May 2018 | lichen sclerosus et atrophicus | Dr Adolf Lukanovič | Unknown | No outcome recorded |
| — | NCT01413477 Comparator | Aug 2011 → Feb 2012 | allergic contact dermatitis | University of British Columbia | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2023-03-23 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064% glenmarkpharma.com ↗
Therefore, with this approval, Glenmark is eligible for 180-days of generic drug exclusivity for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%. |
| 2022-05-09 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064% glenmarkpharma.com ↗
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar® 1 Foam, 0.005%|0.064%, of Leo Pharma AS. |
| 2021-09-29 | MC2 Therapeutics | Results MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021 mc2therapeutics.com ↗
Calcipotriol and betamethasone dipropionate cream demonstrates rapid and clinically meaningful improvement of itch associated with plaque psoriasis |
| 2021-01-13 | Kyowa Kirin, Inc. | Regulatory Approval of Dovobet® Foam for Psoriasis Vulgaris in Japan kyowakirin.com ↗
LEO Pharma K.K. (Head Office: Tokyo; Representative Director: Stefan Sakurai) has received an approval for manufacturing and marketing Dovobet® Foam for the treatment of psoriasis vulgaris |
| 2020-07-22 | MC2 Therapeutics | Regulatory MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for Adults with Plaque Psoriasis mc2therapeutics.com ↗
the U.S. Food and Drug Administration (FDA) has approved Wynzora ® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) |
| 2020-07-16 | MC2 Therapeutics | Regulatory MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora® Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone (as dipropionate) mc2therapeutics.com ↗ |
| 2020-02-14 | Kyowa Kirin, Inc. | Regulatory Sales Collaboration Agreement Reached for Dovobet® Foam Formulation for Psoriasis Vulgaris Treatment in Japan —Marketing Authorization Application Submitted— kyowakirin.com ↗
In addition, LEO Pharma K.K. announced that it applied for marketing authorization for the drug as an additional dosage form of Dovobet® on February 13, 2020. |
| 2019-12-19 | Lupin Limited | Regulatory Lupin receives approval for Betamethasone Dipropionate Ointment USP (Augmented) lupin.com ↗ |
| 2019-12-18 | MC2 Therapeutics | Results MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis mc2therapeutics.com ↗
Wynzora™ Cream demonstrates statistically significantly better treatment efficacy compared to Daivobet® Gel. |
| 2019-11-20 | MC2 Therapeutics | Regulatory MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis mc2therapeutics.com ↗
the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Wynzora™ Cream. |
| 2019-09-24 | MC2 Therapeutics | Regulatory MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis mc2therapeutics.com ↗ |
| 2019-04-04 | Perrigo Company | Regulatory Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05% perrigo.com ↗
today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo ® (betamethasone dipropionate) Spray 0.05%. |
| 2018-08-21 | MC2 Therapeutics | Results MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis mc2therapeutics.com ↗
MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. |
| 2014-07-04 | Kyowa Kirin, Inc. | Regulatory Topical Combination Drug Dovobet® Ointment Approved to Treat Psoriasis Vulgaris kyowakirin.com ↗
This Ointment was approved for the indication of psoriasis vulgaris following clinical studies in Japan that demonstrated the efficacy and safety. |
| 2011-02-22 | Perrigo Company | Regulatory Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma perrigo.com ↗
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a generic form of Taclonex® Ointment. |
All press releases naming this drug 21 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 102 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betamethasone dipropionate | “The combination topical suspension of calcipotriene 0.005% and betamethasone dipropionate 0.064% is a first-line treatment for moderate to severe psoriasis vulgaris and is FDA...” NCT01761019 ↗80“1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from...” NCT05475808 ↗ “fixed-dose combination calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam has been approved (Enstilar®, LEO Pharma) in the USA and EU for the...” PMID 32785881 ↗ Aug 2020 “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 “1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone...” NCT03279796 ↗ “A foam formulation of calcipotriol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 μg/g and betamethasone dipropionate 0.5 mg/g, is approved for the...” PMID 32965655 ↗ Sep 2020 “Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical...” NCT01707043 ↗ “The two-compound topical suspension/gel containing calcipotriene plus betamethasone dipropionate is effective and safe in the treatment of psoriasis on the body and scalp...” PMID 23986161 ↗ Aug 2013 “Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment...” NCT00279162 ↗ “All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone...” NCT01413477 ↗ “The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be...” NCT04000932 ↗ |
| Known as | BD spray 0.05% | “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 |
| Known as | BDP | “combination of calcipotriene (CAL) and betamethasone dipropionate (BDP)” PMID 37490268 ↗ Jul 20231“calcipotriene \[CAL\]/betamethasone dipropionate \[BDP\] ointment” NCT03462927 ↗ |
| Known as | betamethasone | “A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily...” NCT01229098 ↗2“LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)” NCT01866163 ↗ “Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)” NCT03462927 ↗ |
| Known as | Betamethasone diproprionate (0.5% ointment USP generic) | “Betamethasone diproprionate (0.5% ointment USP generic)” NCT01413477 ↗ |
| Known as | Betamethasone-17,21-dipropionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01188928 ↗ |
| Known as | Betnovate | “Atopic dermatitis patients: topical treatment with twice daily full-body ointment containing corticosteroid ("Betnovate", betamethasone dipropionate ointment 0.1%) and placebo” NCT04114097 ↗ |
| Known as | BMDP CREAM | “To assess the safety and efficacy of one (single) application of Betamethasone Dipropionate Nasal Cream (BMDP CREAM) onto the sinus mucosa.” NCT05882903 ↗ |
| Known as | Calcipotriol/betamethasone dipropionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02004574 ↗ |
| Known as | Daivobet | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Known as | DFD-01 | “DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.” NCT02749799 ↗2“DFD-01 (betamethasone dipropionate) Spray, 0.05%” NCT02527421 ↗ “DFD-01 (Betamethasone Dipropionate) Spray 0.05%” NCT02070965 ↗ |
| Known as | diprolene | “Topical medical treatment (Betamethasone dipropionate 0.05% " diprolene " )” NCT04444726 ↗ |
| Known as | Diprolene AF | “Diprolene® AF betamethasone dipropionate 0.05% cream.” NCT00820950 ↗ |
| Known as | Diprosone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525522 ↗ |
| Known as | diprospan | “Thus, the investigators suppose that pre-emptive scalp infiltration with steroid (diprospan) plus local anesthetic (ropivacaine) could relieve postoperative pain after...” NCT04073069 ↗10“Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.” NCT03368274 ↗ “Lidocaine mixed with diprospan injected into tender points.” NCT06344403 ↗ “Injection of steroids (diprospan) intra articularly” NCT02833545 ↗ |
| Known as | Dovobet | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Known as | Rinderon - DP | “Rinderon® - DP = betamethasone dipropionate” NCT01422434 ↗ |
| Known as | Sernivo | “A spray formulation of betamethasone dipropionate 0.05% (BD spray 0.05%; Sernivo™ [betamethasone dipropionate] Spray 0.05%; Promius Pharma, LLC; Princeton, New Jersey, USA) has...” PMID 29657667 ↗ Apr 2018 |
| Known as | Sernivo (betamethasone dipropionate, 0.05%) Spray | “Sernivo (betamethasone dipropionate, 0.05%) Spray” NCT02749799 ↗ |
| Known as | Taclonex | “Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the...” PMID 17135738 ↗ 2006 |
| Modality | Small molecule | “Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema.” NCT01413477 ↗ |
| Route | Topical | “once daily topical treatment for up to 8 weeks” NCT00216840 ↗ |